AstraZeneca, a global biopharmaceutical and biotechnology company, is looking to collaboratively uncover and advance groundbreaking approaches for mitigating nucleotide repeat expansion toxicity.
While the association between nucleotide repeat expansion toxicity and muscle and CNS disorders is well-established, current strategies face challenges in effectively mitigating the toxicity.
AstraZeneca is seeking innovative strategies or novel concepts for mitigating nucleotide repeat expansion toxicity, with the potential to be applied in the treatment of muscle...